MRO Magazine

Praxair Starts up New Air Separation Plant in East China Chemical Park

October 5, 2015 | By Business Wire News

DANBURY, Conn.

Praxair, Inc. (NYSE:PX) announced the start-up of its new air separation plant at the Liaoning Oxiranchem, Inc. (Oxiran) facility in Yangzhou Chemical Industrial Park, Jiangsu Province, China. Praxair is the exclusive industrial gas supplier in the growing chemical park in east China, which has port access to the Yangtze River.

Through a long-term contract, the 600-ton-per-day plant will supply on-site, high-purity oxygen and nitrogen to Oxiran, a leading industrial company focused on the development and sale of ethylene oxide derivative (EOD) chemicals in China. EOD chemicals are used in a variety of applications including the manufacturing of bottles and production of polyester fibers.

“Praxair China is proud to expand upon the strong relationship we have enjoyed with Oxiran for many years,” said John Panikar, president of Praxair Asia. “As the exclusive industrial gas supplier in the park, we look forward to supporting Oxiran’s growth and leadership position in China’s EOD market while also meeting the needs of a diverse set of customers throughout the region.”

About Praxair

Praxair, Inc., a Fortune 250 company with 2014 sales of $12.3 billion, is the largest industrial gases company in North and South America and one of the largest worldwide. The company produces, sells and distributes atmospheric, process and specialty gases, and high-performance surface coatings. Praxair products, services and technologies are making our planet more productive by bringing efficiency and environmental benefits to a wide variety of industries, including aerospace, chemicals, food and beverage, electronics, energy, healthcare, manufacturing, primary metals and many others. More information about Praxair, Inc. is available at www.praxair.com.

Praxair
Kelcey Hoyt, Investors
203-837-2118
kelcey_hoyt@praxair.com
or
Jason Stewart, Media
203-837-2448
jason_stewart@praxair.com

Advertisement

Stories continue below

Print this page